Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.

about

Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.

Item

http://www.wikidata.org/entity/Q41245046

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Involved/uninvolved heavy/ligh ...... ted multiple myeloma patients.

@en

type

Item

label

Involved/uninvolved heavy/ligh ...... ted multiple myeloma patients.

@en

prefLabel

Involved/uninvolved heavy/ligh ...... ted multiple myeloma patients.

@en

P1476

Involved/uninvolved heavy/ligh ...... nted multiple myeloma patients

@en

P2093

A Alegre

http://www.w3.org/2001/XMLSchema#string

A Arteche-López

http://www.w3.org/2001/XMLSchema#string

C Muñoz-Calleja

http://www.w3.org/2001/XMLSchema#string

F J López-Jiménez

http://www.w3.org/2001/XMLSchema#string

M Espiño

http://www.w3.org/2001/XMLSchema#string

M J Blanchard

http://www.w3.org/2001/XMLSchema#string

S Medina

http://www.w3.org/2001/XMLSchema#string

P2860

Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma.

European perspective on multiple myeloma treatment strategies: update following recent congresses

Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma.

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma.

Multiple Myeloma

P2888

bmt.2017.97

P304

1206-1207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2017.97

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Luisa M Villar

P577

2017-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085864133

http://www.w3.org/2001/XMLSchema#string

P698

28581457

http://www.w3.org/2001/XMLSchema#string

P932

5543252

http://www.w3.org/2001/XMLSchema#string